Moderna and BioNTech, once pandemic heroes, are now taking different paths. Moderna focused on mRNA vaccines, while BioNTech diversified into cancer drugs. Both earned $45 billion from Covid vaccines, but Moderna’s stock dropped 72%, while BioNTech’s rose 29%. Moderna cut costs by slashing 10% of its workforce, while BioNTech made deals to expand its portfolio.
Moderna invested in an mRNA pipeline for flu, RSV, and other viruses, but faces challenges as Covid vaccine sales decline. BioNTech acquired a promising bispecific antibody for cancer treatment, partnering with Bristol Myers Squibb for up to $11 billion. Moderna’s focus on mRNA technology led to success during the pandemic, while BioNTech diversified to reduce risk.
Investors await quarterly results from Moderna and BioNTech. Moderna faces challenges as vaccine sales decline, while BioNTech’s cancer drug deals could pay off. BioNTech’s bispecific antibody drug is promising, but faces risks in upcoming trials. Moderna seeks to rebound with flu vaccine sales and FDA approval. Moderna’s focus is on Phase 3 trial for personalized cancer treatment for melanoma, with first interim data possibly available next year. Success could lead to launch in 2027 or 2028. The company’s dependence on vaccines continues, with ongoing patent dispute over Covid-19 shot affecting cash flow. Wall Street awaits outcomes of these strategies.

Read more at CNBC

1. Jobless claims rise to 840,000, exceeding expectations and indicating a slowdown in the labor market recovery.
2. US home sales reach a 14-year high in September, rising 9.4% from the previous month as low mortgage rates drive demand.
3. Tesla reports record third-quarter revenue of $8.77 billion, surpassing analysts’ estimates and delivering over 139,000 vehicles.: Covid vaccine makers Moderna BioNTech stocks, mRNA strategies diverge